- Study protocol
- Open Access
- Open Peer Review
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)
BMC Cancervolume 11, Article number: 329 (2011)
Radical surgery is the cornerstone in the treatment of resectable gastric cancer. The Intergroup 0116 and MAGIC trials have shown benefit of postoperative chemoradiation and perioperative chemotherapy, respectively. Since these trials cannot be compared directly, both regimens are evaluated prospectively in the CRITICS trial. This study aims to obtain an improved overall survival for patients treated with preoperative chemotherapy and surgery by incorporating radiotherapy concurrently with chemotherapy postoperatively.
In this phase III multicentre study, patients with resectable gastric cancer are treated with three cycles of preoperative ECC (epirubicin, cisplatin and capecitabine), followed by surgery with adequate lymph node dissection, and then either another three cycles of ECC or concurrent chemoradiation (45 Gy, cisplatin and capecitabine). Surgical, pathological, and radiotherapeutic quality control is performed. The primary endpoint is overall survival, secondary endpoints are disease-free survival (DFS), toxicity, health-related quality of life (HRQL), prediction of response, and recurrence risk assessed by genomic and expression profiling. Accrual for the CRITICS trial is from the Netherlands, Sweden, and Denmark, and more countries are invited to participate.
Results of this study will demonstrate whether the combination of preoperative chemotherapy and postoperative chemoradiotherapy will improve the clinical outcome of the current European standard of perioperative chemotherapy, and will therefore play a key role in the future management of patients with resectable gastric cancer.
In the Western world, most patients with gastric cancer present with advanced stages of disease, leading to a low 5-year survival of around 25% [1, 2]. After surgical resection, the majority of patients will develop a locoregional recurrence . Many different strategies have been evaluated to improve the outcome of gastric cancer surgery. Randomized trials investigating the role of a more extended lymph node dissection (D2) in comparison with the standard D1 lymphadenectomy, found no difference in overall survival, while a D2 dissection was associated with increased postoperative mortality and morbidity [4–7].
Two Western studies have changed current clinical practice in the treatment of resectable gastric cancer. The Intergroup 0116 study showed a significant benefit in overall survival with adjuvant chemoradiotherapy (CRT) consisting of 45 Gy of radiotherapy combined with fluorouracil (5-FU), and leucovorin, compared to surgery alone . In the British MAGIC (Medical Research Council Adjuvant Gastric Infusional Chemotherapy) study, a significant overall survival benefit was found favouring perioperative chemotherapy (epirubicine, cisplatin, and continuous 5-FU infusion, ECF-regimen) versus surgery alone .
Taken the abovementioned pivotal studies together, the important question that needs to be answered is whether postoperative chemoradiotherapy improves survival as compared to postoperative chemotherapy in patients who are treated with neoadjuvant chemotherapy followed by gastric resection. Due to differences in study design and eligibility criteria between the Intergroup 0116 and the MAGIC study, comparing results of these trials is intrinsically not possible (Table 1). Therefore, the two regimens should be compared in a prospective, randomized manner. This is performed in the currently accruing CRITICS trial (ChemoRadiotherapy after Induction chemoTherapy In Cancer of the Stomach). In the present manuscript, we describe the study protocol of this trial and reflect on the possible implications.
Study design and objectives
The CRITICS study is an international, multicentre, randomized phase III trial. The primary objective is to compare overall survival between patients treated with neoadjuvant chemotherapy followed by surgery and either postoperative chemotherapy or postoperative chemoradiotherapy for resectable gastric cancer (Figure 1). Secondary endpoints include disease-free survival, toxicity, health-related quality of life (HRQL), prediction of response and recurrence risk assessed by genomic and expression profiling. Randomization is performed directly after entering the study, before the administration of preoperative chemotherapy.
The study started in January 2007 and as of May 2011, 350 patients have been included, while a total of 788 is required to meet the H0 hypothesis that the experimental arm with adjuvant chemoradiotherapy improves OS by 10% or more. In the first two years only a few centres in the Netherlands included patients in this trial. At current times, about 50 centres are collaborating, and, besides the Netherlands, Sweden and Denmark are participating countries (clinicaltrials.gov NCT00407186).
Patient selection and preoperative staging
Patients with histologically proven stage Ib-IVa (AJCC 6th edition) gastric adenocarcinoma are eligible for this study. The gastro-oesophageal junction (GEJ) may be involved, but the bulk of the tumour has to be in the stomach. Patients should be at least 18 years old and WHO performance status should be 0 or 1. Patients must have adequate haematological, renal and liver functions as defined in the study protocol. Left ventricular ejection fraction should not be lower than 50%.
Exclusion criteria include: previous malignancy, inoperability due to technical surgery-related factors or general condition, and a solitary functioning kidney within the potential radiation field.
Baseline investigations consist of blood tests, an oesophagogastroduodenoscopy with tumour biopsy samples, computed tomography (CT) of the chest and abdomen, renography, cardiac ejection-fraction scan, electrocardiography, and when the preoperative CT-scan suggests peritoneal carcinomatosis, diagnostic laparoscopy. Endoscopic ultrasonography and a PET-scan are optional.
Randomization is performed with stratification for Lauren classification (intestinal, diffuse, or mixed type adenocarcinoma, or unknown), localization (GEJ, proximal, mid, or distal stomach) and hospital.
Within two weeks after randomization, preoperative chemotherapy is started. All patients are treated with 3 cycles of epirubicin, cisplatin, and capecitabine (ECC). Epirubicin 50 mg/m2 and cisplatin 60 mg/m2 are administered on day 1 intravenously every three weeks, with adequate hydration. Capecitabine is given orally on days 1-14 in a dose of 1000 mg/m2 bid. In Sweden, oxaliplatin 130 mg/m2 is administered instead of cisplatin in order to facilitate chemotherapy administration in the outpatient clinic setting without the need for prehydration. At the start of the study no reimbursement was available for oxaliplatin in the treatment of gastric cancer in the Netherlands.
Response evaluation with CT-scan after two cycles of chemotherapy is aimed primarily to identify patients with early progression.
Surgery is planned 3-6 weeks after the last chemotherapy course. The definitive decision to proceed to surgery is taken based on the absence of signs of progressive disease and an ASA classification of 1 or 2.
Under general anaesthesia supported by epidural anaesthesia, a midline laparotomy is performed, followed by a complete exploration of the abdomen including peritoneal surfaces, liver, and in women, the ovaries. Any free abdominal fluid is aspirated for cytological examination. A curative resection is not possible in case of tumour infiltration into the head of the pancreas requiring a Whipple procedure, para-aortic lymph node metastases below the renal arteries, tumour positive cytology of free peritoneal fluid, or peritoneal metastases that cannot be included in the planned local resection. If curative resection is not possible, the best palliative surgical option is to be decided upon by the surgeon.
Principle of surgery is a wide resection of the tumour bearing part of the stomach (total, subtotal or distal gastrectomy) en bloc with the N1 and N2 lymph nodes (stations 1-9 and 11, Figure 2)  with a minimum of 15 lymph nodes, without routine splenectomy and resection of the pancreatic tail (D1+ lymph node dissection). If possible, a macroscopic proximal and distal margin of 5 cm should be obtained. Adjacent organs are only removed when there is suspicion on tumour involvement.
The continuity of the gastrointestinal tract is restored by a Billroth II reconstruction or with the use of a Roux-en-Y loop. Whether the anastomosis is hand-sutured or stapled is left up to the surgeon. A feeding jejunostomy is strongly advocated and is left in situ until postoperative treatment has been completed and oral intake is adequate.
The specimen is sent to the pathologist, preferably fresh and unopened to enable the collection of fresh frozen tissue, followed by processing and reporting of the specimen according to the study protocol. The pathology report includes a minimal dataset containing the following items: type of tumour, localization and size of tumour, invasion depth, surgical margins, and number of (tumour positive) lymph nodes. All specimens undergo additional central pathology review for grading of histological response .
Between 4-12 weeks following surgery, patients in the control arm are given another 3 courses of ECC. Patients in the experimental arm are treated with radiotherapy combined with capecitabine and cisplatin during five weeks. Capecitabine in this group is administered in a dose of 575 mg/m2 bid from Monday to Friday. Cisplatin is administered at a dose of 20 mg/m2 intravenously with pre- and posthydration weekly. The chemotherapy doses are based on previous dose-finding studies in The Netherlands Cancer Institute [12, 13] (see discussion).
Radiotherapy consists of 45 Gy in 25 fractions of 1.8 Gy with a frequency of five fractions a week. External beam therapy is used to irradiate the tumour bed, anastomoses and regional lymph nodes. The clinical target volume (CTV) has to be delineated on CT-images based on all diagnostic information available.
In defining a planning target volume (PTV), the CTV has to be expanded in all directions with a margin of 10 mm, except towards the vertebrae and kidneys, where a margin of 5 mm is applied. All 3D conformal (or IMRT, intensity modulated radiotherapy) techniques are allowed to get a homogeneous dose distribution in the PTV. AP-PA techniques are judged to be suboptimal and are therefore not allowed.
Target volume delineation manuals and workshops are offered to all participating radiation oncologists. A digital CTV contouring atlas is made available for all local investigators by the study coordinators. Furthermore, all centres are asked to provide CTV contouring and treatment plans of the first three included patients (or of consecutive patients if considered necessary) to the study coordinators before start of treatment, as interobserver variability in CTV delineation for postoperative radiotherapy after gastric resection is large .
Toxicity and adverse events
Toxicity is measured according to NCI Common Toxicity Criteria (CTC), version 3.0. When preoperative chemotherapy is postponed for more than two weeks consecutively, chemotherapy should be discontinued and the patient should proceed to surgery when possible. Dose modification rules are defined in the study protocol .
Serious adverse events are defined according to the rules of good clinical practice and must be reported within one working day.
After treatment, patients are followed by a medical oncologist or gastroenterologist (and radiation oncologist when they received radiotherapy) on a monthly basis during the first three months, followed by three-monthly visits during the rest of the first year and visits every six months until five years of follow-up. Beyond the initial postoperative period, follow-up by the surgeon is planned every 6 months. CT-scanning and renography is performed every 6 months, followed by yearly scans after 2 years of follow-up.
Based on results from the Intergroup 0116  and MAGIC  trials, it is estimated that 5-year overall survival in the perioperative chemotherapy group is 40% and in the chemoradiotherapy group 50%. In order to detect a difference between 40% and 50% in 5-year overall survival with a power of 80% and a significance level of 0.05, about 430 events are required, which corresponds to a total of 788 patients.
Data analysis will be performed according to the intention to treat principle.
An interim analysis is performed when half of the required number of events have been observed.
All patients receive both oral and written information about the study. Randomization can only take place when patients have signed an informed consent. The study is carried out in agreement with the declaration of Helsinki. The study has been approved by the Medical Ethical Committee of the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital.
Local monitoring has been performed for the first three patients in the first ten participating centres and continuation of the monitoring will be performed.
Furthermore, surgical and pathological quality is monitored for every patient, and feedback to the individual surgeons and pathologists on their own performance is used to improve surgical and pathological quality.
Patients fill out quality of life questionnaires EORTC QLQ-C30 and STO22 five times after randomization: before treatment, after preoperative chemotherapy, after surgery, after postoperative therapy and during follow-up after 12 months.
After finishing accrual and survival analysis, the value of the Maruyama Index of unresected disease  and the Memorial Sloan-Kettering Cancer Center (MSKCC) predictive nomogram  will be investigated. Furthermore, collected tumour tissue and serum will be used for genomic profiling and further translational research focussing on prognostic and predictive biomarkers.
In both the British MRC trial [4, 5] and the Dutch Gastric Cancer Trial (DGCT) [6, 7] that randomized gastric cancer patients for a D1 or D2 lymph node dissection, overall survival was not statistically different between the two groups, while a D2 dissection was associated with increased postoperative mortality and morbidity. This might be partially attributed to the higher number of splenectomies and pancreatectomies with a D2 dissection. Another study showed that splenectomy is associated with a twofold risk of postoperative complications .
Therefore, it is suggested that performing a gastrectomy with dissection of at least 15 (N1 and N2) lymph nodes, but without routine splenectomy and resection of the pancreatic tail, a so called D1+ resection, can result in a better outcome . The rationale for a minimum of 15 nodes has been the observation that patients with at least 15 nodes examined have superior survival as compared to patients with fewer nodes examined [20, 21].
While the Intergroup 0116 study, which had no strict surgical quality protocol, was criticized for its low number of per protocol prescribed D2 dissections , in the MAGIC study the percentage of D2 dissections was higher, although no surgical or pathological quality measurements were performed. In the CRITICS study, the Maruyama Index (MI) of unresected disease is used to estimate surgical quality . Also, feedback to individual surgeons and pathologists on their own performance is used to improve surgical and pathological quality.
The Intergroup 0116 study is the key trial supporting the use of postoperative chemoradiotherapy in the potentially curative treatment of gastric cancer . Because of this trial, postoperative CRT is currently a standard option in the United States for patients undergoing curative resection of stage Ib-IV gastric cancer . However, the study has been criticized because it had no strict surgery and pathology quality protocol, suboptimal surgery (with 54% D0 resections while at least a D1 resection should be recommended), a complex, toxic and nowadays outdated chemotherapy schedule with minimal room for interaction with the daily radiation sessions, and the fact that patients were highly selected (only R0 resections with adequate postoperative recovery). In addition, toxicity in the chemoradiotherapy arm was substantial, with only 64% of the patients completing the planned treatment. In a Dutch retrospective study, postoperative chemoradiation after a D2 dissection was not associated with improved survival , in contrast to the results of a large observational Korean study .
Since the Intergroup 0116 study was initiated in the early 90s, the concept of concurrent chemoradiotherapy has nowadays been further developed. Capecitabine, an oral prodrug of 5-FU, mimics continuous infusion of 5-FU, and has proven its feasibility in combination with cisplatin and radiotherapy in several phase I/II studies in advanced, resectable gastric cancer [12, 25], while its systemic exposure was not found to be compromised by the radiation treatment . In these studies, acute toxicity was low, and compliance to the treatment protocol was high (89-100%). The maximum tolerable doses that evolved from these studies are currently used in the CRITICS study. Renal toxicity was addressed in a prospective fashion, showing a reduction in contribution of the left kidney to total renal function in more than half of the patients, especially after 2D radiotherapy techniques . This illustrates the need for precise modern radiotherapy techniques to minimize renal toxicity.
Many studies have been performed with adjuvant chemotherapy in resectable gastric cancer. These studies have been part of several meta-analyses, which could demonstrate no, or at the most a modest survival benefit for adjuvant chemotherapy [28–33]. Newer chemotherapy schedules, with capecitabine and oxaliplatin, have shown to be as least as effective as schedules with 5-FU and cisplatin, with respect to overall survival (REAL-2 study) .
The combination of adjuvant with neo-adjuvant chemotherapy has proven its value in two randomized studies. In the MAGIC study, perioperative chemotherapy resulted in a reduction of the tumour stage, a 10% higher resectability rate and a significant survival benefit of 13% at 5 years . It should be noted that only 55% started postoperative chemotherapy and 42% of the patients completed the entire treatment. The major reasons for a premature treatment stop were tumour progression, postoperative complications, patients' refusal and toxicity. A French prospective trial showed comparable results with 48% of the patients completing the total regimen . The final report of this study has to be awaited. A recent EORTC study comparing preoperative chemotherapy and D2 surgery with D2 surgery alone was stopped early because of poor accrual. A higher R0 resection rate was found in the chemotherapy arm, but no benefit in survival was detected in this underpowered study .
Due to the strong position of perioperative chemotherapy with tumour downsizing and downstaging the CRITICS investigators were reluctant towards a randomization arm without preoperative chemotherapy. Therefore, both arms have the same preoperative chemotherapy schedule. This also leads to comparable resection rates thus eliminating the effect of surgery (and preoperative therapy) on a potential survival difference between the two treatment arms.
With the CRITICS trial, several other studies on the treatment of resectable gastric cancer are ongoing or have just finished. In the currently accruing MAGIC-B study, patients are randomized between perioperative ECC courses with or without bevacizumab. In the Korean ARTIST trial, which finalized accrual, patients were randomized between postoperative chemotherapy with cisplatin and capecitabine versus chemoradiotherapy after a D2 gastric resection. No preoperative therapy was administered. Feasibility data of this study were reported at ASCO-GI 2009 showing good toxicity profiles with compliance rates of 75% versus 82% respectively. Survival data of this trial have to be awaited .
An interesting development is the use of trastuzumab for Her2 positive tumours, which has shown an impressive survival benefit in metastasized gastric cancer . This raises the question if trastuzumab is a valuable addition to the currently used chemotherapy regimens for Her2 positive, resectable gastric cancer. But so far, no such trials have been initiated.
Accrual for the CRITICS study has been expanded to Sweden and Denmark and more countries are invited to participate. It is expected that the results of this study will play a key role in the future treatment of patients with resectable gastric cancer .
Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R: EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer. 2009, 45: 931-991. 10.1016/j.ejca.2008.11.018.
Hundahl SA, Phillips JL, Menck HR: The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer. 2000, 88: 921-932. 10.1002/(SICI)1097-0142(20000215)88:4<921::AID-CNCR24>3.0.CO;2-S.
Gunderson LL: Gastric cancer--patterns of relapse after surgical resection. Semin Radiat Oncol. 2002, 12: 150-161. 10.1053/srao.2002.30817.
Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996, 347: 995-999. 10.1016/S0140-6736(96)90144-0.
Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999, 79: 1522-1530. 10.1038/sj.bjc.6690243.
Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H: Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999, 340: 908-914. 10.1056/NEJM199903253401202.
Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M: Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004, 22: 2069-2077. 10.1200/JCO.2004.08.026.
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001, 345: 725-730. 10.1056/NEJMoa010187.
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006, 355: 11-20. 10.1056/NEJMoa055531.
Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer. 1998, 1: 10-24.
Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M, Kelsen DP, Brennan MF, Coit DG: Does Graded Histologic Response After Neoadjuvant Chemotherapy Predict Survival for Completely Resected Gastric Cancer?. Ann Surg Oncol. 2007, 14: 3412-3418. 10.1245/s10434-007-9574-6.
Jansen EP, Boot H, Dubbelman R, Verheij M, Cats A: Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy. Ann Oncol. 2009, 21: 530-534.
Jansen EPM, Boot H, Dubbelman R, Bartelink H, Cats A, Verheij M: Postoperative chemoradiotherapy in gastric cancer - a phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. Br J Cancer. 2007, 97: 712-716. 10.1038/sj.bjc.6603965.
Jansen EP, Nijkamp J, Gubanski M, Lind PA, Verheij M: Interobserver variation of clinical target volume delineation in gastric cancer. Int J Radiat Oncol Biol Phys. 2010, 77: 1166-1170. 10.1016/j.ijrobp.2009.06.023.
CRITICS website. [http://www.critics.nl]
Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T: Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol. 2002, 9: 278-286. 10.1007/BF02573066.
Kattan MW, Karpeh MS, Mazumdar M, Brennan MF: Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003, 21: 3647-3650. 10.1200/JCO.2003.01.240.
Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Crose N, Gennari L: Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg. 1997, 226: 613-620. 10.1097/00000658-199711000-00006.
van de Velde CJ, Peeters KC: The gastric cancer treatment controversy. J Clin Oncol. 2003, 21: 2234-2236. 10.1200/JCO.2003.91.138.
Karpeh MS, Leon L, Klimstra D, Brennan MF: Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg. 2000, 232: 362-371. 10.1097/00000658-200009000-00008.
Coburn NG, Swallow CJ, Kiss A, Law C: Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer. 2006, 107: 2143-2151. 10.1002/cncr.22229.
Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y: Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006, 4: 350-366.
Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, Boot H, Putter H, Peeters KC, van de Velde CJ, Verheij M: Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010, 28: 2430-2436. 10.1200/JCO.2009.26.9654.
Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, Kim WS, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK, Park K: An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005, 63: 1279-1285. 10.1016/j.ijrobp.2005.05.005.
Jansen EP, Boot H, Dubbelman R, Bartelink H, Cats A, Verheij M: Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. Br J Cancer. 2007, 97: 712-716. 10.1038/sj.bjc.6603965.
Deenen MJ, Boot H, Dubbelman R, Jansen EPM, Beijnen JH, Verheij M, Schellens JHM, Cats A: Effect of gastric surgery and radiotherapy on the exposure to oral capecitabine in patients with gastric cancer. Br J Clin Pharmacol. 2010, 70: 921-922.
Jansen EP, Saunders MP, Boot H, Oppedijk V, Dubbelman R, Porritt B, Cats A, Stroom J, Valdes Olmos R, Bartelink H, Verheij M: Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys. 2007, 67: 781-785. 10.1016/j.ijrobp.2006.09.012.
Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999, 35: 1059-1064. 10.1016/S0959-8049(99)00076-3.
Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, Van de Velde CJ: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993, 11: 1441-1447.
Janunger KG, Hafstrom L, Glimelius B: Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002, 168: 597-608. 10.1080/11024150201680005.
Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol. 2000, 11: 837-843. 10.1023/A:1008377101672.
Panzini I, Gianni L, Fattori PP, Tassinari D, Imola M, Fabbri P, Arcangeli V, Drudi G, Canuti D, Fochessati F, Ravaioli A: Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori. 2002, 88: 21-27.
Sun P, Xiang JB, Chen ZY: Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg. 2009, 96: 26-33. 10.1002/bjs.6408.
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008, 358: 36-46. 10.1056/NEJMoa073149.
Boige V, Pignon JP: Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. ASCO Annual Meeting. 2007
Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Cutsem EV, Siewert JR, Schlag PM: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol. 2010, 28: 5210-5218. 10.1200/JCO.2009.26.6114.
Lee J, Kang W, Lim D: Phase III trial of adjuvant capecitabine/cisplatin (XP) compared with capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis. ASCO Gastrointestinal Cancers Symposium. 2009
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010, 376: 687-697. 10.1016/S0140-6736(10)61121-X.
Kwak EL, Hong TS, Berger DL, Forcione DG, Uppot RN, Lauwers GY: Case records of the Massachusetts General Hospital. Case 19-2009. A 63-year-old woman with carcinoma of the gastroesophageal junction. N Engl J Med. 2009, 360: 2656-2664. 10.1056/NEJMcpc0900638.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/329/prepub
Acknowledgements and funding
Dutch Cancer Society (Data management)
Roche Netherlands (Unrestricted Educational Grant)
Both funding sources have no role in study design, data collection, analysis, interpretation, the writing of the manuscript, or the decision to submit the current study.
This is the first manuscript describing the CRITICS study protocol in detail. Therefore, no related manuscripts are available, except for documentation on http://www.critics.nl.
The authors declare that they have no competing interests.
The study is partly funded by an unrestricted grant from Roche. Roche Netherlands has no role in study design, data collection, analysis, interpretation, the writing of the manuscript, or the decision to submit the current study.
JD drafted the manuscript, JvS, EPMJ, HB, NvG, CJHvdV, MV and AC co-authored the writing of the manuscript. All authors participated in the design of the study and approved the final manuscript.